Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Decitabine

    ... turned off, MDS cells and cancer cells can grow freely. Decitabine is approved by the U.S. Food and Drug Administration (FDA) for ...

    Drug last updated 03/24/2016 - 12:32pm.

  2. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

    ... 23, 2017 Decitabine has been explored as a reduced-intensity therapy for older or ... (AML). To better understand the risk of infections during decitabine treatment, we retrospectively examined the culture results from each ...

    Research Article last updated 11/08/2017 - 9:26am.

  3. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the ...

    Research Article last updated 10/23/2017 - 11:00am.

  4. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the ...

    Research Article last updated 10/02/2017 - 10:03am.

  5. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... the impact of DMT-initiation ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 vs.>3months from start ...

    Research Article last updated 09/13/2017 - 8:58am.

  6. Promising news for older AML patients

    ... untreated AML, the combination of venetoclax with either decitabine or azacitidine was associated with a 69% overall ... in Baltimore. “Venetoclax, when combined with decitabine or azacitidine, has a tolerable safety profile in treatment-naive ...

    Article last updated 07/19/2017 - 11:19am.

  7. Making Progress for Myelodysplastic Syndromes

    ... medications like Vidaza ( azacitidine ), Dacogen ( decitabine ), Revlimid ( lenalidomide ). We consider transplant as a ...

    Article last updated 07/26/2017 - 10:25am.

  8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or ... patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical ...

    Research Article last updated 01/26/2017 - 10:07am.

  9. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... hypomethylating agents (HMAs) azacitidine and decitabine are both approved for treatment of myelodysplastic syndromes (MDS) in the USA. In Europe, decitabine is not approved due to lack of survival advantage in randomized ...

    Research Article last updated 10/06/2016 - 11:34am.

  10. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine

    ... The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes ... neoplasm (MDS/MPN) or AML who were treated with decitabine after primary or secondary azacitidine failure at the University of ...

    Research Article last updated 10/02/2014 - 10:13am.